Treatment and Control of High Blood Pressure in Adults

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 609-622

  Mensah, George A ^a   Bakris, George ^b  

^a PEPSICO INC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antihypertensive medications; Hypertension; Lifestyle modification; Prehypertension

Indexed keywords

ACEBUTOLOL; ADRENALIN; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CANNABINOID 1 RECEPTOR ANTAGONIST; CARVEDILOL; CHLOROTHIAZIDE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; LOOP DIURETIC AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; STEROID; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ANGIONEUROTIC EDEMA; ARTERY DISEASE; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; CAROTID SINUS MASSAGE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY ARTERY DISEASE; CULTURAL FACTOR; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDEMA; EDUCATIONAL STATUS; ENVIRONMENTAL FACTOR; FLUID RETENTION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OBESITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT REFERRAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF CARE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ASPECT; SODIUM RESTRICTION; STROKE; TREATMENT PLANNING; WEIGHT REDUCTION;

ADULT; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIET, SODIUM-RESTRICTED; DIURETICS; DRUG THERAPY, COMBINATION; EXERCISE; FOLLOW-UP STUDIES; FOOD PREFERENCES; HUMANS; HYPERTENSION; LIFE STYLE; MEDICATION ADHERENCE;

EID: 77957727997     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.08.002     Document Type: Review

References (48)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
2. Khan N.A., Hemmelgarn B., Herman R.J., et al. The 2009 Canadian hypertension education program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2009, 25(5):287-298.
3. Padwal R.S., Hemmelgarn B.R., Khan N.A., et al. The 2009 Canadian hypertension education program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009, 25(5):279-286.
4. Sanchez R.A., Ayala M., Baglivo H., et al. Latin American guidelines on hypertension. Latin American Expert Group. J Hypertens 2009, 27(5):905-922.
5. Mancia G., de B.G., Dominiczak A., et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25(9):1751-1762.
6. Japanese Society of Hypertension Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006, 29(Suppl):S1-105. S1-105.
7. Mancia G., de Backer G., Dominiczak A., et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187.
8. Ram C.V., Giles T.D. The evolving definition of systemic arterial hypertension. Curr Atheroscler Rep 2010, 12(3):155-158.
9. Giles T.D., Materson B.J., Cohn J.N., et al. Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich) 2009, 11(11):611-614.
10. Giles T.D. Should we redefine hypertension?. Curr Cardiol Rep 2006, 8(6):395-398.
11. Giles T.D., Berk B.C., Black H.R., et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005, 7(9):505-512.
12. Kostis J.B., Messerli F., Giles T.D. Hypertension: definitions and guidelines. J Clin Hypertens (Greenwich) 2005, 7(9):538-539.
13. Khan N.A., Hemmelgarn B., Herman R.J., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2008, 24(6):465-475.
14. Moore T.J., Alsabeeh N., Apovian C.M., et al. Weight, blood pressure, and dietary benefits after 12 months of a Web-based Nutrition Education Program (DASH for health): longitudinal observational study. J Med Internet Res 2008, 10(4):e52.
15. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002, 288(15):1882-1888.
16. Appel L.J. The role of diet in the prevention and treatment of hypertension. Curr Atheroscler Rep 2000, 2(6):521-528.
17. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344(1):3-10.
18. Ostchega Y., Yoon S.S., Hughes J., et al. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. NCHS Data Brief 2008, (3):1-8.
19. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20):2043-2050.
20. Maruthur N.M., Wang N.Y., Appel L.J. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 2009, 119(15):2026-2031.
21. Mensah G.A. The global burden of hypertension: good news and bad news. Cardiol Clin 2002, 20(2):181-185. v.
22. Chobanian A.V. Shattuck lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009, 361(9):878-887.
23. Rubinstein A., Alcocer L., Chagas A. High blood pressure in Latin America: a call to action. Ther Adv Cardiovasc Dis 2009, 3(4):259-285.
24. Campbell N.R., Leiter L.A., Larochelle P., et al. Hypertension in diabetes: a call to action. Can J Cardiol 2009, 25(5):299-302.
25. Bakris G., Hill M., Mancia G., et al. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens 2008, 22(1):63-70.
26. Lackland D.T. Hypertension control among African Americans: an urgent call for action. J Clin Hypertens (Greenwich) 2004, 6(6):333-334.
27. Carter B.L., Elliott W.J. The role of pharmacists in the detection, management, and control of hypertension: a national call to action. Pharmacotherapy 2000, 20(2):119-122.
28. Lenfant C., Roccella E.J. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999, 17(1):S3-S7.
29. National High Blood Pressure Education Program JNC 7 express: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2003, US Department of Health and Human Services, Bethesda (MD).
30. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417-2428.
31. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348(7):583-592.
32. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
33. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375(9721):1173-1181.
34. Greaves M., Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol 1991, 25(1 Pt 2):155-161.
35. Sica D.A., Black H.R. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?. J Clin Hypertens (Greenwich) 2002, 4(5):375-380.
36. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA/NHLBI 2010 Expert consensus document on hypertension in the elderly: a report of the American College of Cardiology foundation task force on expert consensus documents. J Am Coll Cardiol, in press.
37. Weber M.A., Black H., Bakris G., et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9699):1423-1431.
38. Batkai S., Pacher P., Osei-Hyiaman D., et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004, 110(14):1996-2002.
39. Zieman S.J., Melenovsky V., Clattenburg L., et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007, 25(3):577-583.
40. Bakris G.L., Bank A.J., Kass D.A., et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004, 17(12 Pt 2):23S-30S.
41. Do T.H., Chen Y., Nguyen V.T., et al. Vaccines in the management of hypertension. Expert Opin Biol Ther 2010, 10(7):1077-1087.
42. Ruilope L.M., Dukat A., Bohm M., et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375(9722):1255-1266.
43. Maurer P., Bachmann M.F. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010, 134(1):89-95.
44. Tissot A.C., Maurer P., Nussberger J., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371(9615):821-827.
45. Kougias P., Weakley S.M., Yao Q., et al. Arterial baroreceptors in the management of systemic hypertension. Med Sci Monit 2010, 16(1):RA1-RA8.
46. Oparil S. The sympathetic nervous system in clinical and experimental hypertension. Kidney Int 1986, 30(3):437-452.
47. Schlaich M.P., Krum H., Sobotka P.A. Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension. Curr Hypertens Rep 2010, 12(1):39-46.
48. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373(9671):1275-1281.